Edap Tms (NASDAQ:EDAP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday. The firm currently has a $3.00 price target on the medical equipment provider’s stock. Zacks Investment Research‘s price objective would indicate a potential upside of 11.11% from the company’s previous close.
According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “
A number of other equities analysts have also recently issued reports on the stock. ValuEngine cut shares of Edap Tms from a “hold” rating to a “sell” rating in a research note on Sunday, December 31st. HC Wainwright reaffirmed a “buy” rating and issued a $6.50 price objective on shares of Edap Tms in a research note on Wednesday, November 22nd.
Edap Tms (NASDAQ:EDAP) last announced its quarterly earnings data on Wednesday, November 15th. The medical equipment provider reported ($0.02) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.02). Edap Tms had a negative net margin of 5.36% and a positive return on equity of 7.85%. The firm had revenue of $8.44 million for the quarter, compared to analysts’ expectations of $11.05 million. The firm’s revenue was down 5.6% on a year-over-year basis. analysts forecast that Edap Tms will post -0.01 EPS for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of EDAP. Virtu KCG Holdings LLC acquired a new stake in Edap Tms in the second quarter worth $117,000. Archon Capital Management LLC acquired a new stake in Edap Tms in the second quarter worth $2,474,000. Finally, Essex Investment Management Co. LLC raised its holdings in Edap Tms by 520.2% in the third quarter. Essex Investment Management Co. LLC now owns 323,528 shares of the medical equipment provider’s stock worth $964,000 after purchasing an additional 271,367 shares during the period. Institutional investors own 10.34% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Edap Tms (EDAP) Raised to “Buy” at Zacks Investment Research” was posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.themarketsdaily.com/2018/01/11/edap-tms-edap-raised-to-buy-at-zacks-investment-research.html.
About Edap Tms
EDAP TMS SA (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.